Sun Pharma declares five-year positive results for ILUMYA (tildrakizumab-asmn)
ILUMYA is approved for adults with moderate-to-severe plaque psoriasis and is being evaluated for other possible uses
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Sun Pharmaceutical Industries
Sun Pharma recalls metformin due to high NDMA levels
NDMA is classified as a probable human carcinogen based on results from laboratory tests
DUSA to pay $20.75 mn to resolve allegations related to promotion of actinic keratosis drug
The US DOJ was investigating this issue after a complaint was filed by the company’s former employee in September 2016
Sun Pharma launches generic favipiravir, FluGuard at Rs 35 per tablet
The stocks of FluGuard will be available in the market from this week
Sun Pharma posts Q3FY20 gross sales at Rs 8,039 crores
In Q3, the company registered a net profit of Rs 914 crores Sun Pharmaceutical Industries reported financials for the third…
Sun Pharma launches severe nodular acne management capsules in US
Absorica LD capsules utilises micronised particles to optimise absorption at a 20 per cent lower dose Sun Pharmaceutical…
Sun Pharma launches CEQUA for treatment of dry eye disease in US
Sun Pharma introduces CEQUA SUPPORTTM Specialty Pharmacy programme to enable easy access for patients to obtain treatment Sun…
Sun Pharma presents follow-up data from ILUMYA Phase 3 reSURFACE 1 and 2 trials
Additional data show people with and without metabolic syndrome respond similarly to ILUMYA treatment with comparable, positive…
Sun Pharma arm acquires remaining 3.04 per cent stake in PJSC Biosintez
The company's subsidiary - Sun Pharma (Netherlands) BV - already had 96.96 per cent stake in pharma firm PJSC Biosintez prior to…
Sebi orders forensic audit of Sun Pharma financial statements from FY16-18
Sun Pharma, however, did not provide any specific details on the reasons for the Securities and Exchange Board of India to order…